Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Gilead and Terray Therapeutics Enter Strategic Collaboration for Novel Small Molecule Therapies
Dec 18, 2024•over 1 year ago
Contract Type
partnership
Description
Gilead and Terray Therapeutics have announced a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Terray's tNova platform, which integrates high-throughput chemical experimentation and AI-driven drug discovery, will be utilized to discover and develop small molecule compounds against selected targets by Gilead. Terray will receive upfront payment, milestone payments, and tiered royalties on net sales of products commercialized by Gilead. As a result of this collaboration, Gilead's GAAP and non-GAAP 2024 EPS are expected to reduce by approximately 1c.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months